SARS-CoV2 Archives - Halberd Corporation

Nov 8 2021

Halberd Files Additional Extracorporeal Patent Application: Treatment of Covid-19 By Exposure to Tuned Radio Frequency Waves

By Admin|2021-11-07T19:56:42-05:00November 8th, 2021|Featured, Investor News, News, Press Releases|0 Comments

Jackson Center, PA, November 8, 2021 – Halberd Corporation (OTC-PINK: "HALB") filed a non-provisional patent application for the extracorporeal treatment of Covid-19 through exposure to radio frequency waves. Previously, Halberd filed a provisional patent application on this treatment method. Halberd believes this treatment would be effective against all SARS-CoV-2 variants, and this application preserves Halberd’s ...

May 17 2021

Halberd Corporation Reports Successful Conjugation of Metallic Particles & SARS-CoV-2 Proprietary Monoclonal Antibody

By Admin|2021-05-17T11:12:47-04:00May 17th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, May 17, 2021 – Halberd Corporation (OTC-PINK: "HALB") announces the successful conjugation of gold-coated iron nanoparticles with Halberd’s patent-pending monoclonal antibody against the SARS-CoV-2 spike protein. This milestone paves the way for testing to proceed on the elimination of disease through the application of extracorporeal radio frequency waves or laser emissive energy ...

Jan 14 2021

Halberd Corp. Develops Medication to Boost Immune System Against SARS-CoV-2 (Covid-19)

By Admin|2021-01-13T18:47:16-05:00January 14th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, January 14, 2021 – Halberd Corp. (OTC PINK: "HALB") announced the filing of a provisional patent application on a proprietary combination of nutritional supplements (melatonin, zinc and Vitamin D) combined with low dose Naltrexone designed to reduce the severity of Covid-19 symptoms. This proprietary combination of nutritional supplements is based on numerous ...

Dec 23 2020

Halberd Corporation Produces a Second Monoclonal Antibody Against Covid-19 Spike Protein

By Admin|2020-12-22T21:04:30-05:00December 23rd, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, December 23, 2020 – Halberd Corp. (OTC PINK: "HALB") research has produced a second monoclonal antibody (mAb) against the Covid-19 spike protein. Initial testing displays a stronger affinity for the SARS-CoV-2 antigen than Halberd’s initial antibody. Testing continues through the holidays on each antibody to establish potency and specificity (i.e., targets only ...

Dec 14 2020

Halberd Corp. Research Yields Potent SARS-CoV-2 Antibody

By Admin|2020-12-13T17:40:49-05:00December 14th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, December 14, 2020 – Halberd Corporation (OTC PINK: "HALB") announced its proprietary, highly potent, neutralizing antibody against SARS-CoV-2, which demonstrated very strong receptor specificity and inhibition of SARS-CoV-2 replication. Halberd’s anti-Spike protein monoclonal antibody, recently filed with the United States Patent Office, underwent in vitro studies at Arizona State University (ASU). Based ...

Dec 7 2020

Halberd Corp. Research Yields Promising SARS-CoV-2 Antibody in Laboratory Testing

By Admin|2020-12-06T16:39:08-05:00December 7th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, December 7, 2020 – Halberd Corporation (OTC PINK: "HALB") announced the promising results of laboratory testing on their new patent pending SARS-COV-2 monoclonal antibody generated through their university research. The antibody testing to date has shown extremely potent action against the SARS-CoV-2 spike protein. Scientific details of the testing to date will ...

Dec 2 2020

Halberd Corporation’s Covid-19 Technology Recognized by Momentum Observer

By Admin|2020-12-01T19:46:42-05:00December 2nd, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, December 2, 2020 – Halberd Corp. (OTC PINK: "HALB") was recently included in a Momentum Observer article on Covid-19 along with big pharma companies Pfizer (PFE: NYSE), Moderna (MRNA: NASDAQ), BioNTech (BNTX: NASDAQ) and AstraZeneca (AZN: NASDAQ). The article featured Halberd's nasal spray currently under development that could be an effective alternative ...

Nov 12 2020

Halberd Corporation Reveals Patent-Pending Fluorescent Antibody’s Wide Role in Covid-19 Detection & Treatment

By Admin|2020-11-11T20:25:36-05:00November 12th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, November 12, 2020 – Halberd Corporation (OTC PINK: "HALB") today disclosed information on their patent-pending fluorescent anti-Spike protein monoclonal antibodies against Covid-19 developed in conjunction with Dr. Qiang (Shawn) Chen of Arizona State University. The salient feature of Halberd’s new class of antibody is that it fluoresces in the presence of Covid-19 ...

Oct 13 2020

Arizona State University/Halberd Develop Antibody Against Covid-19

By Admin|2020-10-12T20:32:43-04:00October 13th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, October 13, 2020 – Halberd Corporation (OTC PINK: "HALB") reported that Arizona State University researchers, utilizing the intellectual property of Halberd Corporation, have successfully generated an anti-Spike protein monoclonal antibody against Covid-19. The Spike Protein is a main component of the Covid-19 virus, and is a crucial component in its ability to replicate. ...